martes, 23 de julio de 2013

GLAXO y el sexo (cont.) / Reconoce (y se arrepiente...) de sus "pecados"...

GlaxoSmithKline accused of 'criminal godfather' behaviour in China


GlaxoSmithKline behaved like a criminal "godfather" in China, dispensing some 3 billion yuan (£323m) in bribes since 2007, Chinese police said on Monday.   During a half-year investigation, Chinese police said they had uncovered more than 700 middlemen through which the pharmaceutical giant allegedly funnelled money to health officials and doctors in order to prescribe GSK drugs.

The company also allegedly committed some unspecified "tax-related crimes".

"This company has been investigated for bribery allegations in many countries. From our investigation, bribery is part of the strategy of this company. This is why they have bribery activities in China," said Gao Feng, the head of the economic crimes investigation unit at the Ministry of Public Security.

Four senior GSK executives, all Chinese, are now in detention, Mr Gao said.

According to the Beijing News, the detainees are Zhao Hongyan, 41, GSK's legal counsel and head of compliance, Liang Hong, 49, a vice president in charge of operations, Huang Hong, 45, a general manager in charge of commercial development and Zhang Guowei, 50, the company's human resources director. (Ver)   ...
Imagen: PharmaGossip


GSK says senior executives appear to have broken Chinese law
GlaxoSmithKline said on Monday that some of its executives in China appeared to have broken the law as part of a major bribery scandal that has ensnared the British drugmaker.
The company also said that proposed changes to its operations would result in lower prices of its medicines in China.
"Certain senior executives of GSK China, who know our systems well, appear to have acted outside of our processes and controls which breaches Chinese law," the firm's head of emerging markets, Abbas Hussain, said in a statement.
Hussain, sent to China last week to lead GSK's response to the crisis, held a meeting with the Ministry of Public Security at which he also promised to review GSK's business model.

"Savings made as a result of proposed changes to our operational model will be passed on in the form of price reductions, ensuring our medicines are more affordable to Chinese patients," Hussain added. (Más)

Reconocen culpas...
Y se bajan los p...recios.
Ver tambien:
 
 GSK executive confesses to bribery on chinese television/The Telegraph

China Bars GlaxoSmithKline Executive From Leaving During a Bribery Inquiry

Anterior:

GLAXO y...el sexo.

No hay comentarios: